Ipsen’s Bylvay fails key trial in children with rare liver disease
Phase 3negativeBylvayNegative
AI Analysis
Summary
Ipsen announced that Bylvay failed a Phase 3 trial for biliary atresia, a serious rare liver disease in infants. The negative trial outcome is a significant setback for the drug candidate.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Failed Phase 3 study in children with biliary atresia
Importance:8/10
Sentiment:
-0.90
Phase 3 failurerare diseasepediatric indicationliver disease
Related Companies
Read the original article
Published by Endpoints News on July 24, 2026 3:32 PM